Drug Profile
Research programme: glycogen phosphorylase inhibitors - sanofi-aventis
Alternative Names: AVE 2865; AVE 9423; Glycogen phosphorylase inhibitors research programme - sanofi-aventisLatest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Glycogen phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Europe (unspecified route)
- 26 May 2006 In the latest pipeline of February 24, 2006, sanofi-aventis showed only AVE 9423 in preclinical development
- 26 May 2006 This programme is still in active development